Cargando…

Serum levels of NLRC4 and MCP-2/CCL8 in patients with active Crohn’s disease

Crohn’s disease (CD) is characterized by malfunction of immune-regulatory mechanisms with disturbed intestinal mucosal homeostasis and increased activation of mucosal immune cells, leading to abnormal secretion of numerous pro- and anti-inflammatory mediators. MCP2/CCL8 is produced by intestinal epi...

Descripción completa

Detalles Bibliográficos
Autores principales: Irak, Kader, Bayram, Mehmet, Cifci, Sami, Sener, Gulsen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8598053/
https://www.ncbi.nlm.nih.gov/pubmed/34788319
http://dx.doi.org/10.1371/journal.pone.0260034
_version_ 1784600731170373632
author Irak, Kader
Bayram, Mehmet
Cifci, Sami
Sener, Gulsen
author_facet Irak, Kader
Bayram, Mehmet
Cifci, Sami
Sener, Gulsen
author_sort Irak, Kader
collection PubMed
description Crohn’s disease (CD) is characterized by malfunction of immune-regulatory mechanisms with disturbed intestinal mucosal homeostasis and increased activation of mucosal immune cells, leading to abnormal secretion of numerous pro- and anti-inflammatory mediators. MCP2/CCL8 is produced by intestinal epithelial cells and macrophages, and is a critical regulator of mucosal inflammation. NLRC4 is expressed in phagocytes and intestinal epithelial cells and is involved in intestinal homeostasis and host defense. However, no study to date has assessed the circulating levels of NLRC4 and MCP2/CCL8 in patients with CD. The study was aimed to investigate the serum levels of MCP2/CCL8 and NLRC4 in patients with active CD. Sixty-nine patients with active CD and 60 healthy participants were included in the study. Serum levels of NLRC4 and MCP2/CCL8 were determined using an enzyme-linked immunosorbent assay. The median serum NLRC4 levels were lower in the patient group than in the controls (71.02 (range, 46.59–85.51) pg/mL vs. 99.43 (range 83.52–137.79) pg/mL) (P < 0.001). The median serum levels of MCP2/CCL8 were decreased in patients with CD (28.68 (range, 20.16–46.0) pg/mL) compared with the controls (59.96 (range, 40.22–105.59) pg/mL) (P < 0.001). Cut-off points of NLRC4 (<81 pg/mL) and MCP2/CCL8 (<40 pg/mL) showed high sensitivity and specificity for identifying active CD. In conclusion, this is the first study to examine circulating levels of MCP2/CCL8 and NLRC4 in patients with active CD. Our results suggest that serum NLRC4 and MCP2/CCL8 levels may be involved in the pathogenesis of CD and may have a protective effect on intestinal homeostasis and inflammation. Serum levels of MCP2/CCL8 and NLRC4 could be used as a diagnostic tool and therapeutic target for CD.
format Online
Article
Text
id pubmed-8598053
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-85980532021-11-18 Serum levels of NLRC4 and MCP-2/CCL8 in patients with active Crohn’s disease Irak, Kader Bayram, Mehmet Cifci, Sami Sener, Gulsen PLoS One Research Article Crohn’s disease (CD) is characterized by malfunction of immune-regulatory mechanisms with disturbed intestinal mucosal homeostasis and increased activation of mucosal immune cells, leading to abnormal secretion of numerous pro- and anti-inflammatory mediators. MCP2/CCL8 is produced by intestinal epithelial cells and macrophages, and is a critical regulator of mucosal inflammation. NLRC4 is expressed in phagocytes and intestinal epithelial cells and is involved in intestinal homeostasis and host defense. However, no study to date has assessed the circulating levels of NLRC4 and MCP2/CCL8 in patients with CD. The study was aimed to investigate the serum levels of MCP2/CCL8 and NLRC4 in patients with active CD. Sixty-nine patients with active CD and 60 healthy participants were included in the study. Serum levels of NLRC4 and MCP2/CCL8 were determined using an enzyme-linked immunosorbent assay. The median serum NLRC4 levels were lower in the patient group than in the controls (71.02 (range, 46.59–85.51) pg/mL vs. 99.43 (range 83.52–137.79) pg/mL) (P < 0.001). The median serum levels of MCP2/CCL8 were decreased in patients with CD (28.68 (range, 20.16–46.0) pg/mL) compared with the controls (59.96 (range, 40.22–105.59) pg/mL) (P < 0.001). Cut-off points of NLRC4 (<81 pg/mL) and MCP2/CCL8 (<40 pg/mL) showed high sensitivity and specificity for identifying active CD. In conclusion, this is the first study to examine circulating levels of MCP2/CCL8 and NLRC4 in patients with active CD. Our results suggest that serum NLRC4 and MCP2/CCL8 levels may be involved in the pathogenesis of CD and may have a protective effect on intestinal homeostasis and inflammation. Serum levels of MCP2/CCL8 and NLRC4 could be used as a diagnostic tool and therapeutic target for CD. Public Library of Science 2021-11-17 /pmc/articles/PMC8598053/ /pubmed/34788319 http://dx.doi.org/10.1371/journal.pone.0260034 Text en © 2021 Irak et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Irak, Kader
Bayram, Mehmet
Cifci, Sami
Sener, Gulsen
Serum levels of NLRC4 and MCP-2/CCL8 in patients with active Crohn’s disease
title Serum levels of NLRC4 and MCP-2/CCL8 in patients with active Crohn’s disease
title_full Serum levels of NLRC4 and MCP-2/CCL8 in patients with active Crohn’s disease
title_fullStr Serum levels of NLRC4 and MCP-2/CCL8 in patients with active Crohn’s disease
title_full_unstemmed Serum levels of NLRC4 and MCP-2/CCL8 in patients with active Crohn’s disease
title_short Serum levels of NLRC4 and MCP-2/CCL8 in patients with active Crohn’s disease
title_sort serum levels of nlrc4 and mcp-2/ccl8 in patients with active crohn’s disease
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8598053/
https://www.ncbi.nlm.nih.gov/pubmed/34788319
http://dx.doi.org/10.1371/journal.pone.0260034
work_keys_str_mv AT irakkader serumlevelsofnlrc4andmcp2ccl8inpatientswithactivecrohnsdisease
AT bayrammehmet serumlevelsofnlrc4andmcp2ccl8inpatientswithactivecrohnsdisease
AT cifcisami serumlevelsofnlrc4andmcp2ccl8inpatientswithactivecrohnsdisease
AT senergulsen serumlevelsofnlrc4andmcp2ccl8inpatientswithactivecrohnsdisease